BioCryst Pharmaceuticals, Inc. (BCRX) Financials

BCRX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 517.0 million 972.5 million
2023-09-30 -685.5 million 933.9 million
2023-06-30 529.9 million 918.6 million
2023-03-31 509.7 million 838.0 million

BCRX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -9.5 million 16.5 million
2023-09-30 -20.9 million 12.3 million
2023-06-30 -19.3 million 12.8 million
2023-03-31 -47.7 million 14.0 million

BCRX Net Income

No data available :(

BCRX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 390.8 million - 13.9 million
2023-09-30 397.6 million - 12.2 million
2023-06-30 414.1 million 293.2 million 8.3 million
2023-03-31 401.6 million 232.5 million 8.4 million

BCRX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 201.4 million
2023-09-30 189.6 million
2023-06-30 189.1 million
2023-03-31 188.5 million

BCRX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 554000 69.6 million 64.4 million -
2023-09-30 987000 46.9 million 50.6 million -
2023-06-30 467000 51.2 million 47.7 million 3.3 million
2023-03-31 160000 48.4 million 43.8 million 4.0 million

BCRX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 93.4 million 2.1 million
2023-09-30 86.7 million 1.1 million
2023-06-30 82.5 million 950000
2023-03-31 68.8 million 938000

BCRX

Price: $4.16

52 week price:
4.16
9.07

Earnings Per Share: -1.18 USD

P/E Ratio: -4.06

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 1.7 million

Ebitda: -12.8 million

Market Capitalization: 948.3 million

Links: